Deborah Borst, a 74-year-old resident of Michigan, never fretted over her health, enjoying a life marked by robust well-being. Her hospital visits were limited to the joyous occasions of childbirth.…
Since its founding in 1886, Johnson & Johnson has been dedicated to addressing major health challenges and promoting a healthier world. Today, the company released its 2023 Health for Humanity…
Today marks the launch of “Refer a Friend,” a new feature from Allē, Allergan Aesthetics’ Loyalty Rewards Program. Allē members can now invite friends and family to join, allowing both…
AbbVie announced that RINVOQ® (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis…
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high…
Incyte has finalized its acquisition of Escient Pharmaceuticals, a company specializing in the development of small molecule therapeutics for immune and neuro-immune disorders. The acquisition enhances Incyte’s Inflammation and Autoimmunity…
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has released its 2023 Environmental, Social, and Governance (ESG) Report, showcasing significant advancements in sustainable development. Aligned with…
Shionogi & Co., Ltd. recently announced that its subsidiary, Qpex Biopharma, Inc., has exercised a $10 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This additional…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion,…
Labcorp, a renowned provider of cutting-edge laboratory services globally, is set to unveil multiple abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May…
Today, Astellas announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Biologics License Application (BLA) for zolbetuximab, a groundbreaking investigational monoclonal antibody targeting claudin…
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase…